A clinical trial investigating a cardiac device made by Shockwave Medical, a company being acquired by Johnson & Johnson for $13 billion, provided some support for the device’s effectiveness. The trial, presented at the American College of Cardiology meeting and published in The Lancet, showed that the device, a coronary sinus reducer, reduced angina, but ultimately failed to meet its primary goal. The device aims to reduce chest pain by redirecting blood through the heart’s veins. The results could strengthen the case for the device, which is available in Europe and the U.K. but was previously rejected by the FDA.
Source link
Device from company J&J is buying may reduce chest pain
